<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460256</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Navigating the Landscape of B Cell Mediated Immunity and Antibody Monitoring in SARS-CoV-2 Vaccine Efficacy: Tools, Strategies and Clinical Trial Insights.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1089</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101089</ELocationID><Abstract><AbstractText>Correlates of Protection (CoP) are biomarkers above a defined threshold that can replace clinical outcomes as primary endpoints, predicting vaccine effectiveness to support the approval of new vaccines or follow up studies. In the context of COVID-19 vaccination, CoPs can help address challenges such as demonstrating vaccine effectiveness in special populations, against emerging SARS-CoV-2 variants or determining the durability of vaccine-elicited immunity. While anti-spike IgG titres and viral neutralising capacity have been characterised as CoPs for COVID-19 vaccination, the contribution of other components of the humoral immune response to immediate and long-term protective immunity is less well characterised. This review examines the evidence supporting the use of CoPs in COVID-19 clinical vaccine trials, and how they can be used to define a protective threshold of immunity. It also highlights alternative humoral immune biomarkers, including Fc effector function, mucosal immunity, and the generation of long-lived plasma and memory B cells and discuss how these can be applied to clinical studies and the tools available to study them.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Reilly</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5546-7984</Identifier><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0184-0947</Identifier><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feeney</LastName><ForeName>Eoin R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0003-4118-4945</Identifier><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallon</LastName><ForeName>Patrick W G</ForeName><Initials>PWG</Initials><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gautier</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1862-2644</Identifier><AffiliationInfo><Affiliation>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20/COV/0305</GrantID><Acronym>SFI_</Acronym><Agency>Science Foundation Ireland</Agency><Country>Ireland</Country></Grant><Grant><GrantID>GOIPG/2019/4432</GrantID><Agency>Irish Research Council</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Fc effector functions</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody secreting cells (ASC)</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">clinical vaccine trials</Keyword><Keyword MajorTopicYN="N">correlates of protections</Keyword><Keyword MajorTopicYN="N">humoral immunity</Keyword><Keyword MajorTopicYN="N">immunoglobulins</Keyword><Keyword MajorTopicYN="N">memory B cells</Keyword><Keyword MajorTopicYN="N">neutralising antibodies</Keyword></KeywordList><CoiStatement>E.R.F. has received consulting fees from Gilead, ViiV and Vidacare Ireland, and has been awarded a grant from Science Foundation Ireland. P.W.G.M. has received honoraria and/or travel grants from Gilead Sciences, MSD, Astrazeneca, and ViiV Healthcare, and has been awarded grants by Science Foundation Ireland outside the submitted work. The remaining authors declare that no competing interests exist. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460256</ArticleId><ArticleId IdType="pmc">PMC11511438</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101089</ArticleId><ArticleId IdType="pii">vaccines12101089</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Watson O.J., Barnsley G., Toor J., Hogan A.B., Winskill P., Ghani A.C. Global impact of the first year of COVID-19 vaccination: A mathematical modelling study. Lancet Infect. Dis. 2022;22:1293–1302. doi: 10.1016/S1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobucci G. COVID-19: Vaccines have saved at least 1.4 million lives in Europe, WHO reports. BMJ. 2024;384:q125. doi: 10.1136/bmj.q125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.q125</ArticleId><ArticleId IdType="pubmed">38233071</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis. 2020;20:e192–e197. doi: 10.1016/S1473-3099(20)30483-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruyn G., Wang J., Purvis A., Ruiz M.S., Adhikarla H., Alvi S., Bonaparte M.I., Brune D., Bueso A., Canter R.M., et al. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: A phase 3, parallel-group study. eClinicalMedicine. 2023;62:102109. doi: 10.1016/j.eclinm.2023.102109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102109</ArticleId><ArticleId IdType="pmc">PMC10391925</ArticleId><ArticleId IdType="pubmed">37533419</ArticleId></ArticleIdList></Reference><Reference><Citation>Launay O., Cachanado M., Luong Nguyen L.B., Ninove L., Lachâtre M., Ben Ghezala I., Bardou M., Schmidt-Mutter C., Lacombe K., Laine F., et al. Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine. N. Engl. J. Med. 2022;387:374–376. doi: 10.1056/NEJMc2206711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206711</ArticleId><ArticleId IdType="pmc">PMC9258749</ArticleId><ArticleId IdType="pubmed">35767474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali K., Berman G., Zhou H., Deng W., Faughnan V., Coronado-Voges M., Ding B., Dooley J., Girard B., Hillebrand W., et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N. Engl. J. Med. 2021;385:2241–2251. doi: 10.1056/NEJMoa2109522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109522</ArticleId><ArticleId IdType="pmc">PMC8385554</ArticleId><ArticleId IdType="pubmed">34379915</ArticleId></ArticleIdList></Reference><Reference><Citation>Estrada J.A., Cheng C.Y., Ku S.Y., Hu H.C., Yeh H.W., Lin Y.C., Chen C.P., Cheng S.H., Janssen R., Lin I.F. An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901. Vaccines. 2022;10:655. doi: 10.3390/vaccines10050655.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050655</ArticleId><ArticleId IdType="pmc">PMC9146038</ArticleId><ArticleId IdType="pubmed">35632411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy M.N., Kelly E.J., Seegobin S., Dargan P.I., Payne R., Libri V., Adam M., Aley P.K., Martinez-Alier N., Church A., et al. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: A multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland. Lancet Microbe. 2023;4:e863–e874. doi: 10.1016/s2666-5247(23)00177-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-5247(23)00177-5</ArticleId><ArticleId IdType="pubmed">37783221</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus R., Querton B., Corbic Ramljak I., Dewasthaly S., Jaramillo J.C., Dubischar K., Krammer M., Weisova P., Hochreiter R., Eder-Lingelbach S., et al. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): Interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect. Dis. 2022;22:1716–1727. doi: 10.1016/S1473-3099(22)00502-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00502-3</ArticleId><ArticleId IdType="pmc">PMC9444237</ArticleId><ArticleId IdType="pubmed">36075233</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicines and Healthcare Products Regulatory Agency . Access Consortium: Alignment with ICMRA Consensus on Immunobridging for Authorising New COVID-19 Vaccines. Medicines and Healthcare Products Regulatory Agency; London, UK: 2021.</Citation></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant O.C., Montgomery D., Ito K., Woods R.J. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci. Rep. 2020;10:14991. doi: 10.1038/s41598-020-71748-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-71748-7</ArticleId><ArticleId IdType="pmc">PMC7490396</ArticleId><ArticleId IdType="pubmed">32929138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Schmidt F., Muecksch F., Wang Z., Gazumyan A., Nussenzweig M.C., Gaebler C., Caskey M., Hatziioannou T., Bieniasz P.D. SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity. mBio. 2024;15:e0167223. doi: 10.1128/mbio.01672-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01672-23</ArticleId><ArticleId IdType="pmc">PMC10865855</ArticleId><ArticleId IdType="pubmed">38193662</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L., Gao G.F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 2021;21:73–82. doi: 10.1038/s41577-020-00480-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00480-0</ArticleId><ArticleId IdType="pmc">PMC7747004</ArticleId><ArticleId IdType="pubmed">33340022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh E.E., Frenck R.W., Jr., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439–2450. doi: 10.1056/NEJMoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Keech C., Albert G., Cho I., Robertson A., Reed P., Neal S., Plested J.S., Zhu M., Cloney-Clark S., Zhou H., et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N. Engl. J. Med. 2020;383:2320–2332. doi: 10.1056/NEJMoa2026920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2026920</ArticleId><ArticleId IdType="pmc">PMC7494251</ArticleId><ArticleId IdType="pubmed">32877576</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., et al. An mRNA Vaccine against SARS-CoV-2—Preliminary Report. N. Engl. J. Med. 2020;383:1920–1931. doi: 10.1056/NEJMoa2022483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022483</ArticleId><ArticleId IdType="pmc">PMC7377258</ArticleId><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos R., Rutten L., van der Lubbe J.E.M., Bakkers M.J.G., Hardenberg G., Wegmann F., Zuijdgeest D., de Wilde A.H., Koornneef A., Verwilligen A., et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5:91. doi: 10.1038/s41541-020-00243-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-00243-x</ArticleId><ArticleId IdType="pmc">PMC7522255</ArticleId><ArticleId IdType="pubmed">33083026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.L., Goldsmith J.A., Schaub J.M., DiVenere A.M., Kuo H.C., Javanmardi K., Le K.C., Wrapp D., Lee A.G., Liu Y., et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369:1501–1505. doi: 10.1126/science.abd0826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0826</ArticleId><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M., Chamblee M., Zhang Y., Ye C., Dravid P., Park J.G., Mahesh K.C., Trivedi S., Murthy S., Sharma H., et al. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc. Natl. Acad. Sci. USA. 2022;119:e2110105119. doi: 10.1073/pnas.2110105119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2110105119</ArticleId><ArticleId IdType="pmc">PMC9436349</ArticleId><ArticleId IdType="pubmed">35994646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M., Liu H., Wu N.C., Wilson I.A. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem. Biophys. Res. Commun. 2021;538:192–203. doi: 10.1016/j.bbrc.2020.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.012</ArticleId><ArticleId IdType="pmc">PMC7547570</ArticleId><ArticleId IdType="pubmed">33069360</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameroni E., Bowen J.E., Rosen L.E., Saliba C., Zepeda S.K., Culap K., Pinto D., VanBlargan L.A., De Marco A., di Iulio J., et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022;602:664–670. doi: 10.1038/s41586-021-04386-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04386-2</ArticleId><ArticleId IdType="pmc">PMC9531318</ArticleId><ArticleId IdType="pubmed">35016195</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Zhao X., Zhou H., Zhu H., Jiang S., Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 2023;23:189–199. doi: 10.1038/s41577-022-00784-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00784-3</ArticleId><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F., Thapa M., Lei T., Ahmed S.M.S., Adelsberg D.C., Carreño J.M., Strohmeier S., Schmitz A.J., Zafar S., Zhou J.Q., et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021;184:3936–3948.e3910. doi: 10.1016/j.cell.2021.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.06.005</ArticleId><ArticleId IdType="pmc">PMC8185186</ArticleId><ArticleId IdType="pubmed">34192529</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G., Guo Y., Zhou T., Gorman J., Lee M., Rapp M., Reddem E.R., Yu J., Bahna F., Bimela J., et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021;29:819–833.e7. doi: 10.1016/j.chom.2021.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.005</ArticleId><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Wang F., Li Y., Yan L., Liu L., Zhu W., Ma P., Shi X., Yang G. Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System. Vaccines. 2023;11:771. doi: 10.3390/vaccines11040771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040771</ArticleId><ArticleId IdType="pmc">PMC10143083</ArticleId><ArticleId IdType="pubmed">37112683</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan L.A., Adams L.J., Liu Z., Chen R.E., Gilchuk P., Raju S., Smith B.K., Zhao H., Case J.B., Winkler E.S., et al. A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity. 2021;54:2399–2416.e6. doi: 10.1016/j.immuni.2021.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.08.016</ArticleId><ArticleId IdType="pmc">PMC8373659</ArticleId><ArticleId IdType="pubmed">34481543</ArticleId></ArticleIdList></Reference><Reference><Citation>Dacon C., Tucker C., Peng L., Lee C.D., Lin T.H., Yuan M., Cong Y., Wang L., Purser L., Williams J.K., et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science. 2022;377:728–735. doi: 10.1126/science.abq3773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq3773</ArticleId><ArticleId IdType="pmc">PMC9348754</ArticleId><ArticleId IdType="pubmed">35857439</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva R.P., Huang Y., Nguyen A.W., Hsieh C.L., Olaluwoye O.S., Kaoud T.S., Wilen R.E., Qerqez A.N., Park J.G., Khalil A.M., et al. Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses. eLife. 2023;12:83710. doi: 10.7554/eLife.83710.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.83710</ArticleId><ArticleId IdType="pmc">PMC10030117</ArticleId><ArticleId IdType="pubmed">36942851</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiakolas A.R., Kramer K.J., Wrapp D., Richardson S.I., Schäfer A., Wall S., Wang N., Janowska K., Pilewski K.A., Venkat R., et al. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep. Med. 2021;2:100313. doi: 10.1016/j.xcrm.2021.100313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100313</ArticleId><ArticleId IdType="pmc">PMC8139315</ArticleId><ArticleId IdType="pubmed">34056628</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: From structure to effector functions. Front. Immunol. 2014;5:520. doi: 10.3389/fimmu.2014.00520.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00520</ArticleId><ArticleId IdType="pmc">PMC4202688</ArticleId><ArticleId IdType="pubmed">25368619</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobova Z.R., Zueva E.V., Arsentieva N.A., Batsunov O.K., Liubimova N.E., Khamitova I.V., Kuznetsova R.N., Rubinstein A.A., Savin T.V., Stanevich O.V., et al. Changes in Anti-SARS-CoV-2 IgG Subclasses over Time and in Association with Disease Severity. Viruses. 2022;14:941. doi: 10.3390/v14050941.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14050941</ArticleId><ArticleId IdType="pmc">PMC9143443</ArticleId><ArticleId IdType="pubmed">35632683</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H., Jia T., Chen J., Zeng S., Qiu Z., Wu S., Li X., Lei Y., Wang X., Wu W., et al. The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. Front. Immunol. 2021;12:632814. doi: 10.3389/fimmu.2021.632814.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.632814</ArticleId><ArticleId IdType="pmc">PMC7982848</ArticleId><ArticleId IdType="pubmed">33763078</ArticleId></ArticleIdList></Reference><Reference><Citation>Iles J.K., Zmuidinaite R., Sadee C., Gardiner A., Lacey J., Harding S., Wallis G., Patel R., Roblett D., Heeney J., et al. Determination of IgG1 and IgG3 SARS-CoV-2 Spike Protein and Nucleocapsid Binding-Who Is Binding Who and Why? Int. J. Mol. Sci. 2022;23:6050. doi: 10.3390/ijms23116050.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23116050</ArticleId><ArticleId IdType="pmc">PMC9181569</ArticleId><ArticleId IdType="pubmed">35682724</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Zhang L., Li J., Bai S., Wang Y., Zhang B., Zheng Q., Chen M., Zhao W., Wu J. The kinetics of IgG subclasses and contributions to neutralizing activity against SARS-CoV-2 wild-type strain and variants in healthy adults immunized with inactivated vaccine. Immunology. 2022;167:221–232. doi: 10.1111/imm.13531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13531</ArticleId><ArticleId IdType="pmc">PMC9349727</ArticleId><ArticleId IdType="pubmed">35751471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Pouwels K.B., Stoesser N., Matthews P.C., Diamond I., Studley R., Rourke E., Cook D., Bell J.I., Newton J.N., et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat. Med. 2022;28:1072–1082. doi: 10.1038/s41591-022-01721-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01721-6</ArticleId><ArticleId IdType="pmc">PMC9117148</ArticleId><ArticleId IdType="pubmed">35165453</ArticleId></ArticleIdList></Reference><Reference><Citation>Earle K.A., Ambrosino D.M., Fiore-Gartland A., Goldblatt D., Gilbert P.B., Siber G.R., Dull P., Plotkin S.A. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39:4423–4428. doi: 10.1016/j.vaccine.2021.05.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.063</ArticleId><ArticleId IdType="pmc">PMC8142841</ArticleId><ArticleId IdType="pubmed">34210573</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M., Fragaszy E., Nguyen V., Navaratnam A.M.D., Geismar C., Beale S., Kovar J., Byrne T.E., Fong W.L.E., Patel P., et al. Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. Nat. Commun. 2022;13:5780. doi: 10.1038/s41467-022-33550-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33550-z</ArticleId><ArticleId IdType="pmc">PMC9526787</ArticleId><ArticleId IdType="pubmed">36184633</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew F., Talwar S., Cross A., Willett B.J., Scott S., Logan N., Siggins M.K., Swieboda D., Sidhu J.K., Efstathiou C., et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. eBioMedicine. 2023;87:104402. doi: 10.1016/j.ebiom.2022.104402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104402</ArticleId><ArticleId IdType="pmc">PMC9762734</ArticleId><ArticleId IdType="pubmed">36543718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright P.F., Prevost-Reilly A.C., Natarajan H., Brickley E.B., Connor R.I., Wieland-Alter W.F., Miele A.S., Weiner J.A., Nerenz R.D., Ackerman M.E. Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection. J. Infect. Dis. 2022;226:1204–1214. doi: 10.1093/infdis/jiac065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac065</ArticleId><ArticleId IdType="pmc">PMC8903457</ArticleId><ArticleId IdType="pubmed">35188974</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano K., Bhavsar D., Singh G., Floda D., Srivastava K., Gleason C., Carreño J.M., Simon V., Krammer F. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nat. Commun. 2022;13:5135. doi: 10.1038/s41467-022-32389-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32389-8</ArticleId><ArticleId IdType="pmc">PMC9435409</ArticleId><ArticleId IdType="pubmed">36050304</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J., Zeng C., Cox T.M., Li C., Son Y.M., Cheon I.S., Wu Y., Behl S., Taylor J.J., Chakaraborty R., et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci. Immunol. 2022;7:eadd4853. doi: 10.1126/sciimmunol.add4853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.add4853</ArticleId><ArticleId IdType="pmc">PMC9348751</ArticleId><ArticleId IdType="pubmed">35857583</ArticleId></ArticleIdList></Reference><Reference><Citation>den Hartog G., Andeweg S.P., Hoeve C.E., Smits G., Voordouw B., Eggink D., Knol M.J., van Binnendijk R.S. Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein. Sci. Rep. 2023;13:18394. doi: 10.1038/s41598-023-45718-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-45718-8</ArticleId><ArticleId IdType="pmc">PMC10603038</ArticleId><ArticleId IdType="pubmed">37884642</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Yang M., Peng Y., Liang Y., Wei J., Xing L., Guo L., Li X., Li J., Wang J., et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat. Microbiol. 2022;7:423–433. doi: 10.1038/s41564-021-01051-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-01051-2</ArticleId><ArticleId IdType="pubmed">35132197</ArticleId></ArticleIdList></Reference><Reference><Citation>MacMullan M.A., Ibrayeva A., Trettner K., Deming L., Das S., Tran F., Moreno J.R., Casian J.G., Chellamuthu P., Kraft J., et al. ELISA detection of SARS-CoV-2 antibodies in saliva. Sci. Rep. 2020;10:20818. doi: 10.1038/s41598-020-77555-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77555-4</ArticleId><ArticleId IdType="pmc">PMC7705674</ArticleId><ArticleId IdType="pubmed">33257702</ArticleId></ArticleIdList></Reference><Reference><Citation>Cinquanta L., Fontana D.E., Bizzaro N. Chemiluminescent immunoassay technology: What does it change in autoantibody detection? Auto. Immun. Highlights. 2017;8:9. doi: 10.1007/s13317-017-0097-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13317-017-0097-2</ArticleId><ArticleId IdType="pmc">PMC5483212</ArticleId><ArticleId IdType="pubmed">28647912</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossberg A.N., Koza L.A., Ledreux A., Prusmack C., Krishnamurthy H.K., Jayaraman V., Granholm A.C., Linseman D.A. A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients. Nat. Commun. 2021;12:740. doi: 10.1038/s41467-021-21040-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21040-7</ArticleId><ArticleId IdType="pmc">PMC7854643</ArticleId><ArticleId IdType="pubmed">33531472</ArticleId></ArticleIdList></Reference><Reference><Citation>Gdoura M., Ghaloum F.B., Hamida M.B., Chamsa W., Triki H., Bahloul C. Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans. Sci. Rep. 2022;12:11298. doi: 10.1038/s41598-022-15378-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15378-1</ArticleId><ArticleId IdType="pmc">PMC9252535</ArticleId><ArticleId IdType="pubmed">35788676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G., Negi R., O’Reilly S., Garcia-Leon A., Alalwan D., Gaillard C.M., Saini G., Inzitari R., Feeney E.R., Yousif O., et al. Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination. J. Immunol. Methods. 2022;510:113345. doi: 10.1016/j.jim.2022.113345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2022.113345</ArticleId><ArticleId IdType="pmc">PMC9425705</ArticleId><ArticleId IdType="pubmed">36055441</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins D., Aksyuk A.A., Ruzin A., Tuffy K.M., Green T., Greway R., Fikes B., Bonhomme C.J., Esser M.T., Kelly E.J. Validation and performance of a multiplex serology assay to quantify antibody responses following SARS-CoV-2 infection or vaccination. Clin. Transl. Immunology. 2022;11:e1385. doi: 10.1002/cti2.1385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1385</ArticleId><ArticleId IdType="pmc">PMC9040421</ArticleId><ArticleId IdType="pubmed">35495877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehret R., Breuer S., Dhein J., Reinhardt B., Obermeier M. Clinical evaluation of the automated Abbott RealTime SARS-CoV-2, Alinity m SARS-CoV-2, and Alinity m Resp-4-Plex assays. J. Virol. Methods. 2022;299:114338. doi: 10.1016/j.jviromet.2021.114338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114338</ArticleId><ArticleId IdType="pmc">PMC8532389</ArticleId><ArticleId IdType="pubmed">34695479</ArticleId></ArticleIdList></Reference><Reference><Citation>Syre H., Obreque M.E.B., Dalen I., Riis Å.G., Berg Å., Löhr I.H., Sundal J., Kleppe L.K., Vadla M.S., Lenning O.B., et al. The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection. Viruses. 2022;14:2196. doi: 10.3390/v14102196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102196</ArticleId><ArticleId IdType="pmc">PMC9610468</ArticleId><ArticleId IdType="pubmed">36298751</ArticleId></ArticleIdList></Reference><Reference><Citation>Koup R.A., Donis R.O., Gilbert P.B., Li A.W., Shah N.A., Houchens C.R. A government-led effort to identify correlates of protection for COVID-19 vaccines. Nat. Med. 2021;27:1493–1494. doi: 10.1038/s41591-021-01484-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01484-6</ArticleId><ArticleId IdType="pmc">PMC9095364</ArticleId><ArticleId IdType="pubmed">34518674</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. doi: 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong Y., McDermott A.B., Benkeser D., Roels S., Stieh D.J., Vandebosch A., Le Gars M., Van Roey G.A., Houchens C.R., Martins K., et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat. Microbiol. 2022;7:1996–2010. doi: 10.1038/s41564-022-01262-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01262-1</ArticleId><ArticleId IdType="pmc">PMC10166187</ArticleId><ArticleId IdType="pubmed">36357712</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong Y., Huang Y., Benkeser D., Carpp L.N., Áñez G., Woo W., McGarry A., Dunkle L.M., Cho I., Houchens C.R., et al. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat. Commun. 2023;14:331. doi: 10.1038/s41467-022-35768-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35768-3</ArticleId><ArticleId IdType="pmc">PMC9851580</ArticleId><ArticleId IdType="pubmed">36658109</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Phillips D.J., White T., Sayal H., Aley P.K., Bibi S., Dold C., Fuskova M., Gilbert S.C., Hirsch I., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:2032–2040. doi: 10.1038/s41591-021-01540-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkeser D., Fong Y., Janes H.E., Kelly E.J., Hirsch I., Sproule S., Stanley A.M., Maaske J., Villafana T., Houchens C.R., et al. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. NPJ Vaccines. 2023;8:36. doi: 10.1038/s41541-023-00630-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00630-0</ArticleId><ArticleId IdType="pmc">PMC10005913</ArticleId><ArticleId IdType="pubmed">36899062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M., Park K., Jeong E.J., Shin Y.B., Chung B.H. Surface plasmon resonance imaging analysis of protein-protein interactions using on-chip-expressed capture protein. Anal. Biochem. 2006;351:298–304. doi: 10.1016/j.ab.2006.01.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2006.01.042</ArticleId><ArticleId IdType="pubmed">16510110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H.H., Park J., Kang S., Kim M. Surface plasmon resonance: A versatile technique for biosensor applications. Sensors. 2015;15:10481–10510. doi: 10.3390/s150510481.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/s150510481</ArticleId><ArticleId IdType="pmc">PMC4481982</ArticleId><ArticleId IdType="pubmed">25951336</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeg M., Burti C., Allocati E., Ciafardini C., Banzi R., Nobili A., Caprioli F., Garattini S., Gobbi M. Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera. Sci. Rep. 2021;11:14976. doi: 10.1038/s41598-021-94431-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94431-x</ArticleId><ArticleId IdType="pmc">PMC8298394</ArticleId><ArticleId IdType="pubmed">34294782</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M., Dong T., Han C., Liu L., Zhang T., Kang Q., Wang P., Zhou F. Regenerable and high-throughput surface plasmon resonance assay for rapid screening of anti-SARS-CoV-2 antibody in serum samples. Anal. Chim. Acta. 2022;1208:339830. doi: 10.1016/j.aca.2022.339830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aca.2022.339830</ArticleId><ArticleId IdType="pmc">PMC9006689</ArticleId><ArticleId IdType="pubmed">35525598</ArticleId></ArticleIdList></Reference><Reference><Citation>Schasfoort R.B.M., van Weperen J., van Amsterdam M., Parisot J., Hendriks J., Koerselman M., Karperien M., Mentink A., Bennink M., Krabbe H., et al. High throughput surface plasmon resonance imaging method for clinical detection of presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection. MethodsX. 2021;8:101432. doi: 10.1016/j.mex.2021.101432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mex.2021.101432</ArticleId><ArticleId IdType="pmc">PMC8239317</ArticleId><ArticleId IdType="pubmed">34221910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tut G., Lancaster T., Krutikov M., Sylla P., Bone D., Spalkova E., Bentley C., Amin U., Jadir A., Hulme S., et al. Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes. Nat. Aging. 2023;3:93–104. doi: 10.1038/s43587-022-00328-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-022-00328-3</ArticleId><ArticleId IdType="pmc">PMC10154221</ArticleId><ArticleId IdType="pubmed">37118525</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey T.E., Kemp T.J., Bullock J., Bouk A., Metz J., Neish A., Cherry J., Lowy D.R., Pinto L.A. SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines. Hum. Vaccin. Immunother. 2023;19:2215677. doi: 10.1080/21645515.2023.2215677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2215677</ArticleId><ArticleId IdType="pmc">PMC10305493</ArticleId><ArticleId IdType="pubmed">37264688</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava K., Carreño J.M., Gleason C., Monahan B., Singh G., Abbad A., Tcheou J., Raskin A., Kleiner G., van Bakel H., et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity. 2024;57:587–599.e584. doi: 10.1016/j.immuni.2024.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2024.01.017</ArticleId><ArticleId IdType="pmc">PMC11066813</ArticleId><ArticleId IdType="pubmed">38395697</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers M.A., Olivo A., Harris B.J., Lark C., Luo X., Berg M.G., Meyer T.V., Mohaimani A., Orf G.S., Goldstein Y., et al. Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests. J. Clin. Virol. 2022;147:105080. doi: 10.1016/j.jcv.2022.105080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105080</ArticleId><ArticleId IdType="pmc">PMC8770247</ArticleId><ArticleId IdType="pubmed">35086043</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia A., Crawford K.H.D., Dingens A., Zhu H., Roychoudhury P., Huang M.L., Jerome K.R., Bloom J.D., Greninger A.L. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J. Clin. Microbiol. 2020;58:10-1128. doi: 10.1128/JCM.02107-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02107-20</ArticleId><ArticleId IdType="pmc">PMC7587101</ArticleId><ArticleId IdType="pubmed">32826322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley S.F., O’Donnell D., Stoesser N.E., Matthews P.C., Howarth A., Hatch S.B., Marsden B.D., Cox S., James T., Warren F., et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N. Engl. J. Med. 2021;384:533–540. doi: 10.1056/NEJMoa2034545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034545</ArticleId><ArticleId IdType="pmc">PMC7781098</ArticleId><ArticleId IdType="pubmed">33369366</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K.S., Nason M.C., Flach B., Gagne M., O’Connell S., Johnston T.S., Shah S.N., Edara V.V., Floyd K., Lai L., et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021;373:eabj0299. doi: 10.1126/science.abj0299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj0299</ArticleId><ArticleId IdType="pmc">PMC8449013</ArticleId><ArticleId IdType="pubmed">34529476</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., Chandrashekar A., Zahn R., Wegmann F., Yu J., Mercado N.B., McMahan K., Martinot A.J., Piedra-Mora C., Beecy S., et al. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell. 2021;184:3467–3473.e3411. doi: 10.1016/j.cell.2021.05.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.05.040</ArticleId><ArticleId IdType="pmc">PMC8166510</ArticleId><ArticleId IdType="pubmed">34133941</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Tostanoski L.H., Peter L., Mercado N.B., McMahan K., Mahrokhian S.H., Nkolola J.P., Liu J., Li Z., Chandrashekar A., et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369:806–811. doi: 10.1126/science.abc6284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6284</ArticleId><ArticleId IdType="pmc">PMC7243363</ArticleId><ArticleId IdType="pubmed">32434945</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingler J., Weiss S., Itri V., Liu X., Oguntuyo K.Y., Stevens C., Ikegame S., Hung C.T., Enyindah-Asonye G., Amanat F., et al. Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. J. Infect. Dis. 2021;223:957–970. doi: 10.1093/infdis/jiaa784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa784</ArticleId><ArticleId IdType="pmc">PMC7798948</ArticleId><ArticleId IdType="pubmed">33367897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G., O’Reilly S., Wrigley Kelly N., Negi R., Gaillard C., Alalwan D., Saini G., Alrawahneh T., Francois N., Angeliadis M., et al. Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time. Nat. Commun. 2023;14:7015. doi: 10.1038/s41467-023-42717-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42717-1</ArticleId><ArticleId IdType="pmc">PMC10622572</ArticleId><ArticleId IdType="pubmed">37919289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogando N.S., Dalebout T.J., Zevenhoven-Dobbe J.C., Limpens R., van der Meer Y., Caly L., Druce J., de Vries J.J.C., Kikkert M., Bárcena M., et al. SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology. J. Gen. Virol. 2020;101:925–940. doi: 10.1099/jgv.0.001453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001453</ArticleId><ArticleId IdType="pmc">PMC7654748</ArticleId><ArticleId IdType="pubmed">32568027</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama S., Nao N., Shirato K., Kawase M., Saito S., Takayama I., Nagata N., Sekizuka T., Katoh H., Kato F., et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. USA. 2020;117:7001–7003. doi: 10.1073/pnas.2002589117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2002589117</ArticleId><ArticleId IdType="pmc">PMC7132130</ArticleId><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruetalo N., Businger R., Althaus K., Fink S., Ruoff F., Pogoda M., Iftner A., Ganzenmüller T., Hamprecht K., Flehmig B., et al. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. mSphere. 2021;6:10-1128. doi: 10.1128/mSphere.01145-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.01145-20</ArticleId><ArticleId IdType="pmc">PMC8544894</ArticleId><ArticleId IdType="pubmed">33627511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm A., Widera M., Grikscheit K., Toptan T., Schenk B., Pallas C., Metzler M., Kohmer N., Hoehl S., Marschalek R., et al. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. eBioMedicine. 2022;82:104158. doi: 10.1016/j.ebiom.2022.104158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104158</ArticleId><ArticleId IdType="pmc">PMC9271884</ArticleId><ArticleId IdType="pubmed">35834885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bewley K.R., Coombes N.S., Gagnon L., McInroy L., Baker N., Shaik I., St-Jean J.R., St-Amant N., Buttigieg K.R., Humphries H.E., et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat. Protoc. 2021;16:3114–3140. doi: 10.1038/s41596-021-00536-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-021-00536-y</ArticleId><ArticleId IdType="pubmed">33893470</ArticleId></ArticleIdList></Reference><Reference><Citation>Manenti A., Maggetti M., Casa E., Martinuzzi D., Torelli A., Trombetta C.M., Marchi S., Montomoli E. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J. Med. Virol. 2020;92:2096–2104. doi: 10.1002/jmv.25986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25986</ArticleId><ArticleId IdType="pmc">PMC7267461</ArticleId><ArticleId IdType="pubmed">32383254</ArticleId></ArticleIdList></Reference><Reference><Citation>James J., Rhodes S., Ross C.S., Skinner P., Smith S.P., Shipley R., Warren C.J., Goharriz H., McElhinney L.M., Temperton N., et al. Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies. Viruses. 2021;13:713. doi: 10.3390/v13040713.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040713</ArticleId><ArticleId IdType="pmc">PMC8074400</ArticleId><ArticleId IdType="pubmed">33924168</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A., Edara V.V., Floyd K., Kauffman R.C., Mantus G., Anderson E., Rouphael N., Edupuganti S., Shi P.Y., Menachery V.D., et al. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. Curr. Protoc. Immunol. 2020;131:e116. doi: 10.1002/cpim.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpim.116</ArticleId><ArticleId IdType="pmc">PMC7864545</ArticleId><ArticleId IdType="pubmed">33215858</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Reilly S., Kenny G., Alrawahneh T., Francois N., Gu L., Angeliadis M., de Masson d’Autume V., Garcia Leon A., Feeney E.R., Yousif O., et al. Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening. PLoS ONE. 2023;18:e0294262. doi: 10.1371/journal.pone.0294262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0294262</ArticleId><ArticleId IdType="pmc">PMC10688860</ArticleId><ArticleId IdType="pubmed">38033116</ArticleId></ArticleIdList></Reference><Reference><Citation>Muruato A.E., Fontes-Garfias C.R., Ren P., Garcia-Blanco M.A., Menachery V.D., Xie X., Shi P.Y. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 2020;11:4059. doi: 10.1038/s41467-020-17892-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17892-0</ArticleId><ArticleId IdType="pmc">PMC7426916</ArticleId><ArticleId IdType="pubmed">32792628</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X., Muruato A.E., Zhang X., Lokugamage K.G., Fontes-Garfias C.R., Zou J., Liu J., Ren P., Balakrishnan M., Cihlar T., et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat. Commun. 2020;11:5214. doi: 10.1038/s41467-020-19055-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19055-7</ArticleId><ArticleId IdType="pmc">PMC7567097</ArticleId><ArticleId IdType="pubmed">33060595</ArticleId></ArticleIdList></Reference><Reference><Citation>Abidi S.H., Imtiaz K., Kanji A., Qaiser S., Khan E., Iqbal K., Veldhoen M., Ghias K., Simas J.P., Hasan Z. A rapid real-time polymerase chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against SARS-CoV-2 in blood/serum. PLoS ONE. 2021;16:e0259551. doi: 10.1371/journal.pone.0259551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0259551</ArticleId><ArticleId IdType="pmc">PMC8664206</ArticleId><ArticleId IdType="pubmed">34890401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenegger S., Saiger S., Hardt M., Kulnik S., Wagner G.E., Kleinhappl B., Assig K., Zauner A., Ober M., Kimpel J., et al. Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout. J. Clin. Microbiol. 2022;60:e0037622. doi: 10.1128/jcm.00376-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.00376-22</ArticleId><ArticleId IdType="pmc">PMC9297810</ArticleId><ArticleId IdType="pubmed">35642515</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J., Xia H., Shi P.Y., Xie X., Ren P. A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory. Viruses. 2022;14:1211. doi: 10.3390/v14061211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061211</ArticleId><ArticleId IdType="pmc">PMC9230609</ArticleId><ArticleId IdType="pubmed">35746682</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J., Li Q., Wu J., Zhao C., Hao H., Liu H., Zhang L., Nie L., Qin H., Wang M., et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 2020;15:3699–3715. doi: 10.1038/s41596-020-0394-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0394-5</ArticleId><ArticleId IdType="pubmed">32978602</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D., Steain M., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Kent S.J., Triccas J.A., Khoury D.S., Davenport M.P. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: A meta-analysis. Lancet Microbe. 2022;3:e52–e61. doi: 10.1016/S2666-5247(21)00267-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00267-6</ArticleId><ArticleId IdType="pmc">PMC8592563</ArticleId><ArticleId IdType="pubmed">34806056</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansen P.A., Page M., Bernasconi V., Mattiuzzo G., Dull P., Makar K., Plotkin S., Knezevic I. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397:1347–1348. doi: 10.1016/S0140-6736(21)00527-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00527-4</ArticleId><ArticleId IdType="pmc">PMC7987302</ArticleId><ArticleId IdType="pubmed">33770519</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Schlub T.E., Cromer D., Steain M., Fong Y., Gilbert P.B., Subbarao K., Triccas J.A., Kent S.J., Davenport M.P. Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. Emerg. Infect. Dis. 2023;29:381–388. doi: 10.3201/eid2902.221422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2902.221422</ArticleId><ArticleId IdType="pmc">PMC9881762</ArticleId><ArticleId IdType="pubmed">36692375</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U., Muik A., Vogler I., Derhovanessian E., Kranz L.M., Vormehr M., Quandt J., Bidmon N., Ulges A., Baum A., et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595:572–577. doi: 10.1038/s41586-021-03653-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03653-6</ArticleId><ArticleId IdType="pubmed">34044428</ArticleId></ArticleIdList></Reference><Reference><Citation>Winokur P., Gayed J., Fitz-Patrick D., Thomas S.J., Diya O., Lockhart S., Xu X., Zhang Y., Bangad V., Schwartz H.I., et al. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years. N. Engl. J. Med. 2023;388:214–227. doi: 10.1056/NEJMoa2213082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2213082</ArticleId><ArticleId IdType="pmc">PMC9933930</ArticleId><ArticleId IdType="pubmed">36652353</ArticleId></ArticleIdList></Reference><Reference><Citation>Formica N., Mallory R., Albert G., Robinson M., Plested J.S., Cho I., Robertson A., Dubovsky F., Glenn G.M. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. PLoS Med. 2021;18:e1003769. doi: 10.1371/journal.pmed.1003769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003769</ArticleId><ArticleId IdType="pmc">PMC8486115</ArticleId><ArticleId IdType="pubmed">34597298</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath P.T., Galiza E.P., Baxter D.N., Boffito M., Browne D., Burns F., Chadwick D.R., Clark R., Cosgrove C.A., Galloway J., et al. Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. Clin Infect Dis. 2023;76:398–407. doi: 10.1093/cid/ciac803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac803</ArticleId><ArticleId IdType="pmc">PMC9619635</ArticleId><ArticleId IdType="pubmed">36210481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyke K.E., Atmar R.L., Dominguez Islas C., Posavad C.M., Deming M.E., Branche A.R., Johnston C., El Sahly H.M., Edupuganti S., Mulligan M.J., et al. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. NPJ Vaccines. 2023;8:98. doi: 10.1038/s41541-023-00693-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00693-z</ArticleId><ArticleId IdType="pmc">PMC10336079</ArticleId><ArticleId IdType="pubmed">37433788</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. doi: 10.1016/S0140-6736(20)31604-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31604-4</ArticleId><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Sobieszczyk M.E., Hirsch I., Sproule S., Robb M.L., Corey L., Neuzil K.M., Hahn W., Hunt J., Mulligan M.J., et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 2021;385:2348–2360. doi: 10.1056/NEJMoa2105290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Emary K.R.W., Golubchik T., Aley P.K., Ariani C.V., Angus B., Bibi S., Blane B., Bonsall D., Cicconi P., Charlton S., et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–1362. doi: 10.1016/S0140-6736(21)00628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00628-0</ArticleId><ArticleId IdType="pmc">PMC8009612</ArticleId><ArticleId IdType="pubmed">33798499</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanriover M.D., Doğanay H.L., Akova M., Güner H.R., Azap A., Akhan S., Köse Ş., Erdinç F., Akalın E.H., Tabak Ö.F., et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–222. doi: 10.1016/S0140-6736(21)01429-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01429-X</ArticleId><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng G., Wu Q., Pan H., Li M., Yang J., Wang L., Wu Z., Jiang D., Deng X., Chu K., et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect. Dis. 2022;22:483–495. doi: 10.1016/S1473-3099(21)00681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00681-2</ArticleId><ArticleId IdType="pmc">PMC8651254</ArticleId><ArticleId IdType="pubmed">34890537</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson E.J., Rouphael N.G., Widge A.T., Jackson L.A., Roberts P.C., Makhene M., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N. Engl. J. Med. 2020;383:2427–2438. doi: 10.1056/NEJMoa2028436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028436</ArticleId><ArticleId IdType="pmc">PMC7556339</ArticleId><ArticleId IdType="pubmed">32991794</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>El Sahly H.M., Baden L.R., Essink B., Doblecki-Lewis S., Martin J.M., Anderson E.J., Campbell T.B., Clark J., Jackson L.A., Fichtenbaum C.J., et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N. Engl. J. Med. 2021;385:1774–1785. doi: 10.1056/NEJMoa2113017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2113017</ArticleId><ArticleId IdType="pmc">PMC8482810</ArticleId><ArticleId IdType="pubmed">34551225</ArticleId></ArticleIdList></Reference><Reference><Citation>El Sahly H.M., Baden L.R., Essink B., Montefiori D., McDermont A., Rupp R., Lewis M., Swaminathan S., Griffin C., Fragoso V., et al. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. J. Infect. Dis. 2022;226:1731–1742. doi: 10.1093/infdis/jiac188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac188</ArticleId><ArticleId IdType="pmc">PMC9213865</ArticleId><ArticleId IdType="pubmed">35535503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee I.T., Cosgrove C.A., Moore P., Bethune C., Nally R., Bula M., Kalra P.A., Clark R., Dargan P.I., Boffito M., et al. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: A randomised, observer-blind, active-controlled trial. Lancet Infect. Dis. 2023;23:1007–1019. doi: 10.1016/S1473-3099(23)00295-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00295-5</ArticleId><ArticleId IdType="pubmed">37348519</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter G., Yu J., Liu J., Chandrashekar A., Borducchi E.N., Tostanoski L.H., McMahan K., Jacob-Dolan C., Martinez D.R., Chang A., et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021;596:268–272. doi: 10.1038/s41586-021-03681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03681-2</ArticleId><ArticleId IdType="pmc">PMC8357629</ArticleId><ArticleId IdType="pubmed">34107529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., Cárdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. 2021;384:2187–2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., Cárdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Van Dromme I., Spiessens B., et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N. Engl. J. Med. 2022;386:847–860. doi: 10.1056/NEJMoa2117608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2117608</ArticleId><ArticleId IdType="pmc">PMC8849184</ArticleId><ArticleId IdType="pubmed">35139271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardt K., Vandebosch A., Sadoff J., Le Gars M., Truyers C., Lowson D., Van Dromme I., Vingerhoets J., Kamphuis T., Scheper G., et al. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): Results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect. Dis. 2022;22:1703–1715. doi: 10.1016/S1473-3099(22)00506-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00506-0</ArticleId><ArticleId IdType="pmc">PMC9639796</ArticleId><ArticleId IdType="pubmed">36113538</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chia W.N., Qin X., Liu P., Chen M.I., Tiu C., Hu Z., Chen V.C., Young B.E., Sia W.R., et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 2020;38:1073–1078. doi: 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer B., Reimerink J., Torriani G., Brouwer F., Godeke G.J., Yerly S., Hoogerwerf M., Vuilleumier N., Kaiser L., Eckerle I., et al. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT) Emerg. Microbes Infect. 2020;9:2394–2403. doi: 10.1080/22221751.2020.1835448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1835448</ArticleId><ArticleId IdType="pmc">PMC7605318</ArticleId><ArticleId IdType="pubmed">33043818</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelstein M.T., Mermelstein A.G., Parker Miller E., Seth P.C., Stancofski E.D., Fera D. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses. 2021;13:134. doi: 10.3390/v13010134.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010134</ArticleId><ArticleId IdType="pmc">PMC7833398</ArticleId><ArticleId IdType="pubmed">33477902</ArticleId></ArticleIdList></Reference><Reference><Citation>Seekircher L., Bánki Z., Kimpel J., Rössler A., Schäfer H., Falkensammer B., Bante D., Forer L., Schönherr S., Harthaller T., et al. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: An open-label, observational phase 4 trial. Lancet Microbe. 2023;4:e612–e621. doi: 10.1016/S2666-5247(23)00107-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00107-6</ArticleId><ArticleId IdType="pmc">PMC10284585</ArticleId><ArticleId IdType="pubmed">37354911</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung C.F., Le Bert N., Kam K.Q., Saffari S.E., Tan C.W., Mah Y.Y., Zhang J., Yeoh A.Y., Zhu F., Hariharaputran S., et al. BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: A cohort study. Sci. Rep. 2023;13:17337. doi: 10.1038/s41598-023-44565-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-44565-x</ArticleId><ArticleId IdType="pmc">PMC10575958</ArticleId><ArticleId IdType="pubmed">37833554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J.Z., Tan C.W., Cheng S.M.S., Gu H., Yeoh A.Y.Y., Mok C.K.P., Wang Y., Zhao J., Leung N.H.L., Cowling B.J., et al. Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses. Nat. Commun. 2022;13:6285. doi: 10.1038/s41467-022-34038-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34038-6</ArticleId><ArticleId IdType="pmc">PMC9586968</ArticleId><ArticleId IdType="pubmed">36271047</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Donis R.O., Koup R.A., Fong Y., Plotkin S.A., Follmann D. A Covid-19 Milestone Attained—A Correlate of Protection for Vaccines. N. Engl. J. Med. 2022;387:2203–2206. doi: 10.1056/NEJMp2211314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2211314</ArticleId><ArticleId IdType="pubmed">36507702</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu J., Shen X., Anderson M., Stec M., Petratos T., Cloherty G., Montefiori D.C., Landay A., Moy J.N. Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients. Vaccines. 2022;10:1904. doi: 10.3390/vaccines10111904.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10111904</ArticleId><ArticleId IdType="pmc">PMC9697153</ArticleId><ArticleId IdType="pubmed">36423000</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto A., Miyakawa K., Nakayama I., Yagome S., Xu J., Kaneko M., Ohtake N., Kato H., Ryo A. Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study. Front. Microbiol. 2023;14:1126527. doi: 10.3389/fmicb.2023.1126527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2023.1126527</ArticleId><ArticleId IdType="pmc">PMC10126441</ArticleId><ArticleId IdType="pubmed">37113226</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury S.H., Riley S., Mikolajczyk R., Smith L., Suresh L., Jacobs A. Correlation of SARS-CoV-2 Neutralization with Antibody Levels in Vaccinated Individuals. Viruses. 2023;15:793. doi: 10.3390/v15030793.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030793</ArticleId><ArticleId IdType="pmc">PMC10057460</ArticleId><ArticleId IdType="pubmed">36992501</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D., Fiore-Gartland A., Johnson M., Hunt A., Bengt C., Zavadska D., Snipe H.D., Brown J.S., Workman L., Zar H.J., et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2022;40:306–315. doi: 10.1016/j.vaccine.2021.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.12.006</ArticleId><ArticleId IdType="pmc">PMC8673730</ArticleId><ArticleId IdType="pubmed">34933765</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H.C., Lal K.G., Balinsky C.A., Hontz R.D., Lin J., Beye M.J., Smith L., Pan L., Cheng Y., Fox I., et al. Informing the Need for a SARS-CoV-2 Booster Based Upon the Immune Responses among Young Healthy Adults to Variants Circulating in Late 2023. J. Infect. Dis. 2024;230:645–656. doi: 10.1093/infdis/jiae249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiae249</ArticleId><ArticleId IdType="pubmed">38718223</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Nicols A., Turtle L., Richter A., Duncan C.J., Dunachie S.J., Klenerman P., Payne R.P. T cell immune memory after covid-19 and vaccination. BMJ Med. 2023;2:e000468. doi: 10.1136/bmjmed-2022-000468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000468</ArticleId><ArticleId IdType="pmc">PMC10668147</ArticleId><ArticleId IdType="pubmed">38027416</ArticleId></ArticleIdList></Reference><Reference><Citation>Almendro-Vázquez P., Laguna-Goya R., Paz-Artal E. Defending against SARS-CoV-2: The T cell perspective. Front. Immunol. 2023;14:1107803. doi: 10.3389/fimmu.2023.1107803.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1107803</ArticleId><ArticleId IdType="pmc">PMC9911802</ArticleId><ArticleId IdType="pubmed">36776863</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 2022;23:186–193. doi: 10.1038/s41590-021-01122-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul P., El-Naas A., Hamad O., Salameh M.A., Mhaimeed N., Laswi I., Abdelati A.A., AlAnni J., Khanjar B., Al-Ali D., et al. Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. Hum. Vaccin. Immunother. 2023;19:2167410. doi: 10.1080/21645515.2023.2167410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2167410</ArticleId><ArticleId IdType="pmc">PMC10054360</ArticleId><ArticleId IdType="pubmed">36915960</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang A., Stacey H.D., D’Agostino M.R., Tugg Y., Marzok A., Miller M.S. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat. Rev. Immunol. 2023;23:381–396. doi: 10.1038/s41577-022-00813-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00813-1</ArticleId><ArticleId IdType="pmc">PMC9761659</ArticleId><ArticleId IdType="pubmed">36536068</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahavi D., AlDeghaither D., O’Connell A., Weiner L.M. Enhancing antibody-dependent cell-mediated cytotoxicity: A strategy for improving antibody-based immunotherapy. Antib. Ther. 2018;1:7–12. doi: 10.1093/abt/tby002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abt/tby002</ArticleId><ArticleId IdType="pmc">PMC7990127</ArticleId><ArticleId IdType="pubmed">33928217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay M.Z., Wiehe K., Pollara J. Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses. Front. Immunol. 2019;10:332. doi: 10.3389/fimmu.2019.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00332</ArticleId><ArticleId IdType="pmc">PMC6404786</ArticleId><ArticleId IdType="pubmed">30873178</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34–50. doi: 10.1038/cr.2009.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2009.139</ArticleId><ArticleId IdType="pubmed">20010915</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauzin A., Nayrac M., Benlarbi M., Gong S.Y., Gasser R., Beaudoin-Bussières G., Brassard N., Laumaea A., Vézina D., Prévost J., et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe. 2021;29:1137–1150.e1136. doi: 10.1016/j.chom.2021.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.001</ArticleId><ArticleId IdType="pmc">PMC8175625</ArticleId><ArticleId IdType="pubmed">34133950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W.S., Selva K.J., Davis S.K., Wines B.D., Reynaldi A., Esterbauer R., Kelly H.G., Haycroft E.R., Tan H.X., Juno J.A., et al. Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Rep. Med. 2021;2:100296. doi: 10.1016/j.xcrm.2021.100296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100296</ArticleId><ArticleId IdType="pmc">PMC8106889</ArticleId><ArticleId IdType="pubmed">33997824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman K.A., Stein D., Shin S., Ferbas K.G., Tobin N.H., Mann C., Fischinger S., Ollmann Saphire E., Lauffenburger D., Rimoin A.W., et al. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. mBio. 2022;13:e0164722. doi: 10.1128/mbio.01647-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01647-22</ArticleId><ArticleId IdType="pmc">PMC9600672</ArticleId><ArticleId IdType="pubmed">36000735</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams L.E., Leist S.R., Dinnon K.H., 3rd, West A., Gully K.L., Anderson E.J., Loome J.F., Madden E.A., Powers J.M., Schäfer A., et al. Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. Cell Rep. 2023;42:112326. doi: 10.1016/j.celrep.2023.112326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112326</ArticleId><ArticleId IdType="pmc">PMC10063157</ArticleId><ArticleId IdType="pubmed">37000623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hederman A.P., Natarajan H., Heyndrickx L., Ariën K.K., Wiener J.A., Wright P.F., Bloch E.M., Tobian A.A.R., Redd A.D., Blankson J.N., et al. SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations. Nat. Commun. 2023;14:5171. doi: 10.1038/s41467-023-40960-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40960-0</ArticleId><ArticleId IdType="pmc">PMC10449910</ArticleId><ArticleId IdType="pubmed">37620337</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong X., McNamara R.P., Avendaño M.J., Serrano E.F., García-Salum T., Pardo-Roa C., Bertera H.L., Chicz T.M., Levican J., Poblete E., et al. Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination. Nat. Commun. 2023;14:4174. doi: 10.1038/s41467-023-39189-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39189-8</ArticleId><ArticleId IdType="pmc">PMC10345146</ArticleId><ArticleId IdType="pubmed">37443074</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaudoin-Bussières G., Richard J., Prévost J., Goyette G., Finzi A. A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells. STAR Protoc. 2021;2:100851. doi: 10.1016/j.xpro.2021.100851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2021.100851</ArticleId><ArticleId IdType="pmc">PMC8435374</ArticleId><ArticleId IdType="pubmed">34541555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y., Guo H., Wei M., Zhang Y., Fang M., Cheng T., Li Z., Ge S., Yao X., Yuan Q., et al. Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein. J. Virol. Methods. 2022;307:114564. doi: 10.1016/j.jviromet.2022.114564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2022.114564</ArticleId><ArticleId IdType="pmc">PMC9167684</ArticleId><ArticleId IdType="pubmed">35671888</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A.L., Fallon J.K., Alter G. A Sample-Sparing Multiplexed ADCP Assay. Front. Immunol. 2019;10:1851. doi: 10.3389/fimmu.2019.01851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01851</ArticleId><ArticleId IdType="pmc">PMC6700248</ArticleId><ArticleId IdType="pubmed">31456799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerman M.E., Moldt B., Wyatt R.T., Dugast A.S., McAndrew E., Tsoukas S., Jost S., Berger C.T., Sciaranghella G., Liu Q., et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods. 2011;366:8–19. doi: 10.1016/j.jim.2010.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2010.12.016</ArticleId><ArticleId IdType="pmc">PMC3050993</ArticleId><ArticleId IdType="pubmed">21192942</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsten C.B., Mehta N., Shin S.A., Diefenbach T.J., Slein M.D., Karpinski W., Irvine E.B., Broge T., Suscovich T.J., Alter G. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. J. Immunol. Methods. 2019;471:46–56. doi: 10.1016/j.jim.2019.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2019.05.006</ArticleId><ArticleId IdType="pmc">PMC6620195</ArticleId><ArticleId IdType="pubmed">31132351</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown E.P., Dowell K.G., Boesch A.W., Normandin E., Mahan A.E., Chu T., Barouch D.H., Bailey-Kellogg C., Alter G., Ackerman M.E. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. J. Immunol. Methods. 2017;443:33–44. doi: 10.1016/j.jim.2017.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2017.01.010</ArticleId><ArticleId IdType="pmc">PMC5333794</ArticleId><ArticleId IdType="pubmed">28163018</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown E.P., Licht A.F., Dugast A.S., Choi I., Bailey-Kellogg C., Alter G., Ackerman M.E. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods. 2012;386:117–123. doi: 10.1016/j.jim.2012.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2012.09.007</ArticleId><ArticleId IdType="pmc">PMC3475184</ArticleId><ArticleId IdType="pubmed">23023091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischinger S., Fallon J.K., Michell A.R., Broge T., Suscovich T.J., Streeck H., Alter G. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods. 2019;473:112630. doi: 10.1016/j.jim.2019.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2019.07.002</ArticleId><ArticleId IdType="pmc">PMC6722412</ArticleId><ArticleId IdType="pubmed">31301278</ArticleId></ArticleIdList></Reference><Reference><Citation>Haycroft E.R., Davis S.K., Ramanathan P., Lopez E., Purcell R.A., Tan L.L., Pymm P., Wines B.D., Hogarth P.M., Wheatley A.K., et al. Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants. Med. Microbiol. Immunol. 2023;212:291–305. doi: 10.1007/s00430-023-00773-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-023-00773-w</ArticleId><ArticleId IdType="pmc">PMC10372118</ArticleId><ArticleId IdType="pubmed">37477828</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch Y.C., St Denis K.J., Kaplonek P., Kang J., Lam E.C., Burns M.D., Farkas E.J., Davis J.P., Boribong B.P., Edlow A.G., et al. SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children. Sci. Transl. Med. 2022;14:eabn9237. doi: 10.1126/scitranslmed.abn9237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn9237</ArticleId><ArticleId IdType="pmc">PMC9348753</ArticleId><ArticleId IdType="pubmed">35881018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daëron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716–3725. doi: 10.1182/blood-2008-09-179754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-09-179754</ArticleId><ArticleId IdType="pubmed">19018092</ArticleId></ArticleIdList></Reference><Reference><Citation>Rispens T., Huijbers M.G. The unique properties of IgG4 and its roles in health and disease. Nat. Rev. Immunol. 2023;23:763–778. doi: 10.1038/s41577-023-00871-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00871-z</ArticleId><ArticleId IdType="pmc">PMC10123589</ArticleId><ArticleId IdType="pubmed">37095254</ArticleId></ArticleIdList></Reference><Reference><Citation>Buhre J.S., Pongracz T., Künsting I., Lixenfeld A.S., Wang W., Nouta J., Lehrian S., Schmelter F., Lunding H.B., Dühring L., et al. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. Front. Immunol. 2022;13:1020844. doi: 10.3389/fimmu.2022.1020844.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1020844</ArticleId><ArticleId IdType="pmc">PMC9877300</ArticleId><ArticleId IdType="pubmed">36713457</ArticleId></ArticleIdList></Reference><Reference><Citation>Irrgang P., Gerling J., Kocher K., Lapuente D., Steininger P., Habenicht K., Wytopil M., Beileke S., Schäfer S., Zhong J., et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 2023;8:eade2798. doi: 10.1126/sciimmunol.ade2798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.ade2798</ArticleId><ArticleId IdType="pmc">PMC9847566</ArticleId><ArticleId IdType="pubmed">36548397</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar M., Islam M.R., Khaton F., Soltana U.H., Jafrin S.A., Rahman S.I.A., Tauheed I., Ahmed T., Khan I.I., Akter A., et al. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Front. Immunol. 2023;14:1309997. doi: 10.3389/fimmu.2023.1309997.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1309997</ArticleId><ArticleId IdType="pmc">PMC10763240</ArticleId><ArticleId IdType="pubmed">38173725</ArticleId></ArticleIdList></Reference><Reference><Citation>Espino A.M., Armina-Rodriguez A., Alvarez L., Ocasio-Malavé C., Ramos-Nieves R., Rodriguez Martinó E.I., López-Marte P., Torres E.A., Sariol C.A. The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine. Viruses. 2024;16:187. doi: 10.3390/v16020187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16020187</ArticleId><ArticleId IdType="pmc">PMC10893502</ArticleId><ArticleId IdType="pubmed">38399963</ArticleId></ArticleIdList></Reference><Reference><Citation>Röltgen K., Nielsen S.C.A., Silva O., Younes S.F., Zaslavsky M., Costales C., Yang F., Wirz O.F., Solis D., Hoh R.A., et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185:1025–1040.e1014. doi: 10.1016/j.cell.2022.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.018</ArticleId><ArticleId IdType="pmc">PMC8786601</ArticleId><ArticleId IdType="pubmed">35148837</ArticleId></ArticleIdList></Reference><Reference><Citation>Noval M.G., Kaczmarek M.E., Koide A., Rodriguez-Rodriguez B.A., Louie P., Tada T., Hattori T., Panchenko T., Romero L.A., Teng K.W., et al. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. Sci. Rep. 2021;11:5538. doi: 10.1038/s41598-021-84913-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84913-3</ArticleId><ArticleId IdType="pmc">PMC7946906</ArticleId><ArticleId IdType="pubmed">33692390</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohar T., Loos C., Fischinger S., Atyeo C., Wang C., Slein M.D., Burke J., Yu J., Feldman J., Hauser B.M., et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell. 2020;183:1508–1519.e1512. doi: 10.1016/j.cell.2020.10.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.052</ArticleId><ArticleId IdType="pmc">PMC7608014</ArticleId><ArticleId IdType="pubmed">33207184</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sousa-Pereira P., Woof J.M. IgA: Structure, Function, and Developability. Antibodies. 2019;8:57. doi: 10.3390/antib8040057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib8040057</ArticleId><ArticleId IdType="pmc">PMC6963396</ArticleId><ArticleId IdType="pubmed">31817406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani A., Horie T., Yokoyama R., Nakano Y., Hamada K., Inoue Y., Saito M., Ishii T., Sunohara M., Takahashi R., et al. Interpretations of SARS-CoV-2 IgM and IgG antibody titers in the seroepidemiological study of asymptomatic healthy volunteers. J. Infect. Chemother. 2022;28:266–272. doi: 10.1016/j.jiac.2021.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2021.11.020</ArticleId><ArticleId IdType="pmc">PMC8648596</ArticleId><ArticleId IdType="pubmed">34887175</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggiero A., Piubelli C., Calciano L., Accordini S., Valenti M.T., Carbonare L.D., Siracusano G., Temperton N., Tiberti N., Longoni S.S., et al. SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals. eBioMedicine. 2022;77:103888. doi: 10.1016/j.ebiom.2022.103888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103888</ArticleId><ArticleId IdType="pmc">PMC8858081</ArticleId><ArticleId IdType="pubmed">35196644</ArticleId></ArticleIdList></Reference><Reference><Citation>Piubelli C., Ruggiero A., Calciano L., Mazzi C., Castilletti C., Tiberti N., Caldrer S., Verzè M., Longoni S.S., Accordini S., et al. Subjects who developed SARS-CoV-2 specific IgM after vaccination show a longer humoral immunity and a lower frequency of infection. eBioMedicine. 2023;89:104471. doi: 10.1016/j.ebiom.2023.104471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104471</ArticleId><ArticleId IdType="pmc">PMC9925293</ArticleId><ArticleId IdType="pubmed">36796232</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhury S., Hutter J., Bolton J.S., Hakre S., Mose E., Wooten A., O’Connell W., Hudak J., Krebs S.J., Darden J.M., et al. Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform. PLoS ONE. 2021;16:e0252628. doi: 10.1371/journal.pone.0252628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0252628</ArticleId><ArticleId IdType="pmc">PMC8174743</ArticleId><ArticleId IdType="pubmed">34081747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Lorenzi J.C.C., Muecksch F., Finkin S., Viant C., Gaebler C., Cipolla M., Hoffmann H.H., Oliveira T.Y., Oren D.A., et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 2021;13:eabf1555. doi: 10.1126/scitranslmed.abf1555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf1555</ArticleId><ArticleId IdType="pmc">PMC7857415</ArticleId><ArticleId IdType="pubmed">33288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser R., Orta-Resendiz A., Mazein A., Dockrell D.H. Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. Trends Mol. Med. 2023;29:255–267. doi: 10.1016/j.molmed.2023.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2023.01.003</ArticleId><ArticleId IdType="pmc">PMC9868365</ArticleId><ArticleId IdType="pubmed">36764906</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.T., Kwan A.T., Rodríguez-Barraquer I., Singer B.J., Park H.J., Lewnard J.A., Sears D., Lo N.C. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat. Med. 2023;29:358–365. doi: 10.1038/s41591-022-02138-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02138-x</ArticleId><ArticleId IdType="pmc">PMC9974584</ArticleId><ArticleId IdType="pubmed">36593393</ArticleId></ArticleIdList></Reference><Reference><Citation>Stouten V., Hubin P., Haarhuis F., van Loenhout J.A.F., Billuart M., Brondeel R., Braeye T., Van Oyen H., Wyndham-Thomas C., Catteau L. Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium. Viruses. 2022;14:802. doi: 10.3390/v14040802.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14040802</ArticleId><ArticleId IdType="pmc">PMC9029338</ArticleId><ArticleId IdType="pubmed">35458532</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanatidou E., Gkiouliava A., Pella E., Serafidi M., Tsilingiris D., Vallianou N.G., Karampela I., Dalamaga M. Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. Metabol. Open. 2022;14:100180. doi: 10.1016/j.metop.2022.100180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2022.100180</ArticleId><ArticleId IdType="pmc">PMC8928742</ArticleId><ArticleId IdType="pubmed">35313532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh-Mohamed S., Isho B., Chao G.Y.C., Zuo M., Cohen C., Lustig Y., Nahass G.R., Salomon-Shulman R.E., Blacker G., Fazel-Zarandi M., et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. 2022;15:799–808. doi: 10.1038/s41385-022-00511-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-022-00511-0</ArticleId><ArticleId IdType="pmc">PMC9037584</ArticleId><ArticleId IdType="pubmed">35468942</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel O., Rockstroh A., Wolf J., Landgraf S., Kalbitz S., Kellner N., Borte M., Pietsch C., Fertey J., Lübbert C., et al. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2. PLoS ONE. 2022;17:e0263861. doi: 10.1371/journal.pone.0263861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263861</ArticleId><ArticleId IdType="pmc">PMC9578597</ArticleId><ArticleId IdType="pubmed">36256664</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzi L., Dalla Gasperina D., Veronesi G., Shallak M., Ietto G., Iovino D., Baj A., Gianfagna F., Maurino V., Focosi D., et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. eBioMedicine. 2022;75:103788. doi: 10.1016/j.ebiom.2021.103788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103788</ArticleId><ArticleId IdType="pmc">PMC8718969</ArticleId><ArticleId IdType="pubmed">34954658</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S., Marking U., Svensson J., Greilert-Norin N., Bacchus P., Nilsson P., Hober S., Gordon M., Blom K., Klingström J., et al. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. N. Engl. J. Med. 2022;387:1333–1336. doi: 10.1056/NEJMc2209651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209651</ArticleId><ArticleId IdType="pmc">PMC9511632</ArticleId><ArticleId IdType="pubmed">36103621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Huang S., Liu X., Chen Q., Zhuang C., Zhao H., Han J., Jaen A.M., Do T.H., Peter J.G., et al. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2023;11:1075–1088. doi: 10.1016/S2213-2600(23)00349-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00349-1</ArticleId><ArticleId IdType="pmc">PMC10682370</ArticleId><ArticleId IdType="pubmed">37979588</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing M., Hu G., Wang X., Wang Y., He F., Dai W., Niu Y., Liu J., Liu H., Zhang X., et al. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza. NPJ Vaccines. 2024;9:64. doi: 10.1038/s41541-024-00857-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00857-5</ArticleId><ArticleId IdType="pmc">PMC10954707</ArticleId><ArticleId IdType="pubmed">38509167</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler J.M., Martin Vidal R., Langner C., Vladimirova D., Abdelgawad A., Kunecova D., Lin X., Nouailles G., Voss A., Kunder S., et al. An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission. Nat. Commun. 2024;15:995. doi: 10.1038/s41467-024-45348-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-45348-2</ArticleId><ArticleId IdType="pmc">PMC10837132</ArticleId><ArticleId IdType="pubmed">38307868</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore A.P.S., St John A.L. Promises and challenges of mucosal COVID-19 vaccines. Vaccine. 2023;41:4042–4049. doi: 10.1016/j.vaccine.2023.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.04.013</ArticleId><ArticleId IdType="pmc">PMC10083204</ArticleId><ArticleId IdType="pubmed">37045682</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilapitiya D., Wheatley A.K., Tan H.X. Mucosal vaccines for SARS-CoV-2: Triumph of hope over experience. eBioMedicine. 2023;92:104585. doi: 10.1016/j.ebiom.2023.104585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104585</ArticleId><ArticleId IdType="pmc">PMC10154910</ArticleId><ArticleId IdType="pubmed">37146404</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Riaño A., Bovolenta E.R., Mendoza P., Oeste C.L., Martín-Bermejo M.J., Bovolenta P., Turner M., Martínez-Martín N., Alarcón B. Antigen phagocytosis by B cells is required for a potent humoral response. EMBO Rep. 2018;19:e46016. doi: 10.15252/embr.201846016.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201846016</ArticleId><ArticleId IdType="pmc">PMC6123646</ArticleId><ArticleId IdType="pubmed">29987136</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong S., Ruprecht R.M. Immunoglobulin M: An Ancient Antiviral Weapon—Rediscovered. Front. Immunol. 2020;11:1943. doi: 10.3389/fimmu.2020.01943.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01943</ArticleId><ArticleId IdType="pmc">PMC7432194</ArticleId><ArticleId IdType="pubmed">32849652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.Y., Wolf J., Brice D.C., Sun Y., Locke M., Cherry S., Castellaw A.H., Wehenkel M., Crawford J.C., Zarnitsyna V.I., et al. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell Host Microbe. 2022;30:83–96.e84. doi: 10.1016/j.chom.2021.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.12.005</ArticleId><ArticleId IdType="pmc">PMC8648673</ArticleId><ArticleId IdType="pubmed">34965382</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T., Kurosaki T. Memory B cells. Nat. Rev. Immunol. 2024;24:5–17. doi: 10.1038/s41577-023-00897-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00897-3</ArticleId><ArticleId IdType="pubmed">37400644</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Yang C., Jia G., Liu Y., Wang N., Yang F., Su R., Shang Y., Han Y. Comprehensive evaluation of the effects of long-term cryopreservation on peripheral blood mononuclear cells using flow cytometry. BMC Immunol. 2022;23:30. doi: 10.1186/s12865-022-00505-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-022-00505-4</ArticleId><ArticleId IdType="pmc">PMC9175382</ArticleId><ArticleId IdType="pubmed">35672664</ArticleId></ArticleIdList></Reference><Reference><Citation>Serra V., Fiorillo E., Cucca F., Orru V. Quantifying the Detrimental Effects of Multiple Freeze/Thaw Cycles on Primary Human Lymphocyte Survival and Function. Int. J. Mol. Sci. 2022;24:634. doi: 10.3390/ijms24010634.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24010634</ArticleId><ArticleId IdType="pmc">PMC9820337</ArticleId><ArticleId IdType="pubmed">36614075</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon M.M.L., Rybkina K., Kato Y., Kubota M., Matsumoto R., Bloom N.I., Zhang Z., Hastie K.M., Grifoni A., Weiskopf D., et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci. Immunol. 2021;6:eabl9105. doi: 10.1126/sciimmunol.abl9105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl9105</ArticleId><ArticleId IdType="pmc">PMC8626868</ArticleId><ArticleId IdType="pubmed">34618554</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng W., Zhang B., Schwartz G.W., Rosenfeld A.M., Ren D., Thome J.J.C., Carpenter D.J., Matsuoka N., Lerner H., Friedman A.L., et al. An atlas of B-cell clonal distribution in the human body. Nat. Biotechnol. 2017;35:879–884. doi: 10.1038/nbt.3942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3942</ArticleId><ArticleId IdType="pmc">PMC5679700</ArticleId><ArticleId IdType="pubmed">28829438</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisel N.M., Weisel F.J., Farber D.L., Borghesi L.A., Shen Y., Ma W., Luning Prak E.T., Shlomchik M.J. Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype. Blood. 2020;136:2774–2785. doi: 10.1182/blood.2019002782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019002782</ArticleId><ArticleId IdType="pmc">PMC7731793</ArticleId><ArticleId IdType="pubmed">32750113</ArticleId></ArticleIdList></Reference><Reference><Citation>Czerkinsky C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods. 1983;65:109–121. doi: 10.1016/0022-1759(83)90308-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-1759(83)90308-3</ArticleId><ArticleId IdType="pubmed">6361139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouers A., Tay M.Z., Ng L.F.P., Renia L. B-cell ELISpot assay to analyze human memory B cell and plasmablast responses specific to SARS-CoV-2 receptor-binding domain. STAR Protoc. 2023;4:102130. doi: 10.1016/j.xpro.2023.102130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2023.102130</ArticleId><ArticleId IdType="pmc">PMC9910018</ArticleId><ArticleId IdType="pubmed">36853725</ArticleId></ArticleIdList></Reference><Reference><Citation>Donatella Negri P.S., Borghi M., Ciccolella M., Bracci L. In: Methods in Enzymology. Lorenzo Galluzzi N.-P.R., editor. Academic Press; Cambridge, MA, USA: 2020. pp. 457–477.</Citation><ArticleIdList><ArticleId IdType="pubmed">32000910</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamm L.M., Dahlke C., Addo M.M. Flow cytometric protocol to characterize human memory B cells directed against SARS-CoV-2 spike protein antigens. STAR Protoc. 2022;3:101902. doi: 10.1016/j.xpro.2022.101902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2022.101902</ArticleId><ArticleId IdType="pmc">PMC9663734</ArticleId><ArticleId IdType="pubmed">36595922</ArticleId></ArticleIdList></Reference><Reference><Citation>Waltari E., McGeever A., Friedland N., Kim P.S., McCutcheon K.M. Functional Enrichment and Analysis of Antigen-Specific Memory B Cell Antibody Repertoires in PBMCs. Front. Immunol. 2019;10:1452. doi: 10.3389/fimmu.2019.01452.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01452</ArticleId><ArticleId IdType="pmc">PMC6603168</ArticleId><ArticleId IdType="pubmed">31293598</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Z., Luo W., Chen R., Li Y., Wang Z., Liu Y., Liu S., Feng L., Jia Z., Cheng R., et al. Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds. Signal Transduct. Target. Ther. 2023;8:179. doi: 10.1038/s41392-023-01422-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01422-7</ArticleId><ArticleId IdType="pmc">PMC10157553</ArticleId><ArticleId IdType="pubmed">37142583</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zeng Q., Deng C., Li M., Li L., Liu D., Liu M., Ruan X., Mei J., Mo R., et al. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine. Cell Discov. 2022;8:10. doi: 10.1038/s41421-022-00373-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-022-00373-7</ArticleId><ArticleId IdType="pmc">PMC8803973</ArticleId><ArticleId IdType="pubmed">35102140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciabattini A., Pastore G., Lucchesi S., Montesi G., Costagli S., Polvere J., Fiorino F., Pettini E., Lippi A., Ancillotti L., et al. Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine. Cells. 2023;12:1706. doi: 10.3390/cells12131706.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12131706</ArticleId><ArticleId IdType="pmc">PMC10340653</ArticleId><ArticleId IdType="pubmed">37443740</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne J., Gu L., Garcia-Leon A., Gaillard C.M., Saini G., Alalwan D., Tomás-Cortázar J., Kenny G., Donohue S., Reynolds B., et al. Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection. Front. Immunol. 2024;15:1445653. doi: 10.3389/fimmu.2024.1445653.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1445653</ArticleId><ArticleId IdType="pmc">PMC11442242</ArticleId><ArticleId IdType="pubmed">39355249</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L.S., Ash N., Alroy-Preis S., Huppert A., Milo R. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N. Engl. J. Med. 2022;386:2201–2212. doi: 10.1056/NEJMoa2118946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118946</ArticleId><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier A.Y., Brown C.M., McMahan K.A., Yu J., Liu J., Jacob-Dolan C., Chandrashekar A., Tierney D., Ansel J.L., Rowe M., et al. Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Sci. Transl. Med. 2022;14:eabn6150. doi: 10.1126/scitranslmed.abn6150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn6150</ArticleId><ArticleId IdType="pmc">PMC8995036</ArticleId><ArticleId IdType="pubmed">35258323</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Apostolidis S.A., Painter M.M., Mathew D., Pattekar A., Kuthuru O., Gouma S., Hicks P., Meng W., Rosenfeld A.M., et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci. Immunol. 2021;6:eabi6950. doi: 10.1126/sciimmunol.abi6950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abi6950</ArticleId><ArticleId IdType="pmc">PMC8158969</ArticleId><ArticleId IdType="pubmed">33858945</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds C.J., Pade C., Gibbons J.M., Butler D.K., Otter A.D., Menacho K., Fontana M., Smit A., Sackville-West J.E., Cutino-Moguel T., et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;372:1418–1423. doi: 10.1126/science.abh1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1282</ArticleId><ArticleId IdType="pmc">PMC8168614</ArticleId><ArticleId IdType="pubmed">33931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsi E., Diniz M.O., Reine J., Collins A.M., Robinson R.E., Hyder-Wright A., Farrar M., Liatsikos K., Hamilton J., Onyema O., et al. Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination. Nat. Commun. 2023;14:6815. doi: 10.1038/s41467-023-42433-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42433-w</ArticleId><ArticleId IdType="pmc">PMC10603102</ArticleId><ArticleId IdType="pubmed">37884506</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Muecksch F., Schaefer-Babajew D., Finkin S., Viant C., Gaebler C., Hoffmann H.H., Barnes C.O., Cipolla M., Ramos V., et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595:426–431. doi: 10.1038/s41586-021-03696-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03696-9</ArticleId><ArticleId IdType="pmc">PMC8277577</ArticleId><ArticleId IdType="pubmed">34126625</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernyshev M., Sakharkar M., Connor R.I., Dugan H.L., Sheward D.J., Rappazzo C.G., Stalmarck A., Forsell M.N.E., Wright P.F., Corcoran M., et al. Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages. Nat. Commun. 2023;14:2249. doi: 10.1038/s41467-023-37972-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37972-1</ArticleId><ArticleId IdType="pmc">PMC10115384</ArticleId><ArticleId IdType="pubmed">37076511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A., Barba-Spaeth G., Fernandez I., Broketa M., Azzaoui I., de La Selle A., Vandenberghe A., Fourati S., Roeser A., Meola A., et al. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity. 2021;54:2893–2907.e2895. doi: 10.1016/j.immuni.2021.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.011</ArticleId><ArticleId IdType="pmc">PMC8452492</ArticleId><ArticleId IdType="pubmed">34614412</ArticleId></ArticleIdList></Reference><Reference><Citation>Quandt J., Muik A., Salisch N., Lui B.G., Lutz S., Kruger K., Wallisch A.K., Adams-Quack P., Bacher M., Finlayson A., et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci. Immunol. 2022;7:eabq2427. doi: 10.1126/sciimmunol.abq2427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq2427</ArticleId><ArticleId IdType="pmc">PMC9162083</ArticleId><ArticleId IdType="pubmed">35653438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz A.R., Fiebig L., Hirseland H., Diekmann L.M., Reinke S., Hardt S., Niedobitek A., Mei H.E. SARS-CoV-2 specific plasma cells acquire long-lived phenotypes in human bone marrow. eBioMedicine. 2023;95:104735. doi: 10.1016/j.ebiom.2023.104735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104735</ArticleId><ArticleId IdType="pmc">PMC10432952</ArticleId><ArticleId IdType="pubmed">37556944</ArticleId></ArticleIdList></Reference><Reference><Citation>Halperin S.A., Ye L., MacKinnon-Cameron D., Smith B., Cahn P.E., Ruiz-Palacios G.M., Ikram A., Lanas F., Lourdes Guerrero M., Muñoz Navarro S.R., et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399:237–248. doi: 10.1016/s0140-6736(21)02753-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)02753-7</ArticleId><ArticleId IdType="pmc">PMC8700283</ArticleId><ArticleId IdType="pubmed">34953526</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>